ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION A Treat-and-Extend Protocol Over 2 Years
ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION A Treat-and-Extend Protocol Over 2 Years
复制标题
DOI：
10.1097/iae.0000000000000134
复制
发表时间：
2014-08-01
影响因子：
3.3
通讯作者：
Guymer, Robyn H.
中科院分区：
文献类型：
--
作者：
Abedi, Farshad;Wickremasinghe, Sanjeewa;Guymer, Robyn H.
目的：评价抗血管内皮生长因子治疗老年性黄斑变性（age-related macular degeneration.Methods）的治疗和扩展方案的2年视力结果：在这项前瞻性队列研究中，120例伴有脉络膜新生血管的老年性黄斑变性患者接受了3个月的初始雷珠单抗或贝伐单抗注射;每月注射一次，直到没有脉络膜新生血管形成活动（视网膜下/视网膜内液体，>5个字母的丢失，或持续/复发性视网膜出血）。当没有脉络膜新生血管形成活动时，至下一次访视/注射的间隔延长2周，最长为12周。在存在脉络膜新生血管活动的情况下，该间隔缩短了2周。主要观察指标包括：
Purpose: To evaluate 2-year visual acuity outcome of a treat-and-extend protocol of anti-vascular endothelial growth factor treatment in age-related macular degeneration.Methods: In this prospective cohort study, 120 age-related macular degeneration patients with choroidal neovascularization received 3 initial monthly ranibizumab or bevacizumab injections; monthly injections were continued until there was no choroidal neovascularization activity (subretinal/intraretinal fluid, loss of >5 letters, or persistent/recurrent retinal hemorrhage). When there was no choroidal neovascularization activity, the interval to the next visit/injection was extended by 2 weeks to a maximum of 12 weeks. In the presence of choroidal neovascularization activity, this interval was shortened by 2 weeks. Main outcome measures included the percentage losing